Oncology Highlights – 30/07/2018

Notizia - Recent Pharma, Healthcare and Biotech Happenings

KEY CLINICAL OUTCOMES

Streamlined solutions provided by Cognitive Clinical Trials (CCT) related to the treatment and prevention of Alzheimer’s disease Congnitive Clinical Trials (CCT) has introduced a new research model...

Oct 11, 2018

FDA
Copiktra receives approval; Lilly wins approval; Eisai’s Fycompa; Astellas’ Roxadustat; Janssen’s Esketamine Nasal Spray

SNAPSHOTS: Copiktra receives FDA approval for CLL and FL, Relief for tazemetostat developers after FDA lifted partial clinical hold, Conference highlights from 19th WCLC The United States Food and Drug Administration (USFDA) has granted approval to Verastem’s Copiktra (duvelisib), for the treatment of patients with...

Find More
Orchard files for IPO; J&J puts money on RNA interference; Rgenix receives $40M; GSK gives a helping hand

Orchard files for USD173 Million IPO to run pivotal gene therapy trials Orchard Therapeutics, Transatlantic biotech, has filed to raise USD 173 million in an IPO. This will lead it to take three gene therapies through the clinic. Orchard recognised itself as one of the broadest clinical-phase gene therapy pipelines ...

Find More
Notizia

FDA approves transthyretin amyloidosis therapy of Akcea, Ionis Patients with an orphan, hereditary disease that is transthyretin amyloidosis with a second new treatment option are available after the Food and Drug Administration approved Akcea Therapeutics and Ionis Pharmaceuticals' Tegsedi.  As Tegsedi is approved,...

Find More

More Views & Analysis

Johnson & Johnson
Hologic complements Focal; Allogene for IPO; Gamida, Novartis-backed cell therapy startup; Aduro loses partner

Hologic complements Focal Therapeutics to its breast-conserving surgery for USD 125 Million Hologic, a global champion of women's health based in Massachusetts, United States, is taking possession of Focal Therapeutics, a medical device company, for USD 125 million to complement its breast-conserving surgery permit...

Find More

Johnson & Johnson
Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune

Ceribell raises USD 35 Million in series B round Ceribell, Emergency EEG maker raised USD 35 million for commercializing its EEG system that can rapidly diagnose patients, who are supposed of not having convulsive seizures with no visual symptoms for the use in neurological intensive care units and emergency rooms. ...

Find More

transthyretin amyloidosis
Notizia

The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...

Find More

Johnson & Johnson
Epic Sciences garners; Tvardi gets financing; Galera raises; Fund for cancer research

Epic Sciences garners USD 52 Million for blood tests in cancer patients Epic Sciences received USD 52 million to progress its suite of liquid biopsies that utilizes computer vision and machine learning to find circulating tumour cells while characterizing the immune response of the body at the same time. The Cancer...

Find More

transthyretin amyloidosis
Notizia

Argenx gets green cue in phase 2 in primary immune thrombocytopenia The Belgian biotech, Argenx has cleared phase 2 data on efgartigimod in primary immune thrombocytopenia (ITP). The results that they received, indicate at the effectiveness of the antibody Fc fragment in patients with the autoimmune bleeding disord...

Find More

Johnson & Johnson
Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M

Atreca secured USD 125 Million when solid tumor trial comes into picture California based company, Atreca has bagged USD 125 million to establish its R&D activities. As the company gears up, the series C round enters, to move its lead solid tumor drug into the clinic.  Atreca has set up its credentials through V...

Find More

A formal medical disorder affecting approximately 10 percent of the world population is trypanophobi.....

Find More

Atrial fibrillation market is brimming with novel therapies in different stages of clinical developm.....

Find More

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hyperten.....

Find More

With its innovative approach, chimeric antigen receptor T cell therapy created a new dawn in the age.....

Find More

Peanut Allergy accounts for the majority of severe food-associated allergic reactions. It is strictl.....

Find More

With worldwide dissemination and now over 9 million cases and nearly 500,000 deaths recorded, the ef.....

Find More